Groups | n | Cyst area (mm) using digimizer measurement | Cyst area (mm) using CT scan measurement | |||
---|---|---|---|---|---|---|
 |  | Mean ± SD before treatment | Mean ± SD after treatment | Mean ± SD before treatment | Mean ± SD after treatment | P value (Student’s t-test) |
CEI1: treated with curcumin nanoemulsion (CUR-NE) (40 mg/kg/day) | 6 | Lack of access to secondary cysts | 30.33 ± 21.91 | 25.83 ± 6.8 | 23.66 ± 6.25 | 0.063 |
CEI2: treated with CUR-NE (20 mg/kg/day) | 6 | Lack of access to secondary cysts | 49.83 ± 18.11 | 24.83 ± 6.46 | 26.58 ± 8.02 | 0.499 |
CEI3: treated with NE without CUR (NE-no CUR) | 6 | Lack of access to secondary cysts | 57.5 ± 25.28 | 29.5 ± 9.93 | 29.66 ± 10.52 | 0.95 |
CEI4: treated with curcumin suspension (CUR-S) (40 mg/kg/day) | 6 | Lack of access to secondary cysts | 35.66 ± 20.81 | 27.3 ± 5.56 | 26.6 ± 7.17 | 0.75 |
CEI5: treated with ABZ (150 mg/kg/day) (PC1) | 6 | Lack of access to secondary cysts | 50.66 ± 20.37 | 26.16 ± 7.74 | 24.58 ± 7.39 | 0.217 |
CEI6: received sterile PBS (NC2) | 4 | Lack of access to secondary cysts | 67.75 ± 28.84 | 24.41 ± 6.64 | 26.41 ± 8.08 | 0.033* |